Interní Med. 2010; 12(3): 126-130

Pharmacological management of chronic heart failure

doc.MUDr.Radek Pudil, Ph.D.
I. interní klinika LF UK a FN, Hradec Králové

In the last years, the number of patients with chronic heart failure is increasing. Heart failure is a frequent cause of hospitalizations. Despite

the progress in therapy, heart failure has high rate of hospitalization admissions and mortality. Pharmacological management can

significantly improve the course of the disease. The article is a review of pharmacotherapy of chronic heart failure, it discuss indications

of the drugs and pitfalls of the therapy. Therapy of chronic heart failure is rather complex, it requires identification of the cause and

precipitating factors, which can make it worsen.

Keywords: chronic heart failure, angiotensin converting enzyme inhibitors, sartans, beta-blockers, diuretics, digitalis

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pudil R. Pharmacological management of chronic heart failure. Interní Med. 2010;12(3):126-130.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93: 1137-1146. Go to original source... Go to PubMed...
    2. Aschermann M, a kol. Kardiologie. Praha: Galén, 2004: 1481.
    3. Málek I. Léčba chronického srdečního selhání. In: Vojáček, a kol. Klinická kardiologie. Nukleus Hradec Králové 2009: 401-414.
    4. Špinar J, Hradec J, Meluzín J. Doporučení pro diagnostiku a léčbu chronického srdečního selhání ČKS 2006. Cor Vasa 2007; 49(1): K5-K34.
    5. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Eur J Heart Fail 2008; 10: 933-989. Go to original source... Go to PubMed...
    6. Shlipak MG. Pharmacotherapy for Heart Failure in Patients with Renal Insuficiency. Ann Int Med. 2003; 138: 917-924. Go to original source... Go to PubMed...
    7. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-380. Go to original source...
    8. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-2199. Go to original source... Go to PubMed...
    9. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13. Go to original source... Go to PubMed...
    10. López-Sendón J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341-1362. Go to original source... Go to PubMed...
    11. Vítovec J, Špinar J. Diuretika u srdečního selhání. Kapit Kardiol 2002; 4: 90-92.
    12. Gheorghiade M, Gattis WA, O'Connor ChM. Effects of Tolvaptan a Vassopresin Antagonist, in Patients Hospitalized With Worsening Heart Failure. Randomized Controlled Trial. JAMA 2004; 291: 1963-1971. Go to original source... Go to PubMed...
    13. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-1321. Go to original source... Go to PubMed...
    14. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999; 341: 709-717. Go to original source... Go to PubMed...
    15. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871-878. Go to original source... Go to PubMed...
    16. The effect of digoxin on mortality and morbidity in patients with heart failure. The digitalis investigation group. N Engl J Med. 1997; 336: 525-533.
    17. Cleland JGF, Findlay I, Jafri S, et al. The Warfarin/Aspirin Study in Heart Failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004; 148: 157-164. Go to original source... Go to PubMed...
    18. Táborský M, Kautzner J, Bytešník J, et al. Zásady implantace kardiostimulátorů, implantabilních kardioverterů-defibrilátorů a systémů pro resynchronizační léčbu 2009. Cor Vasa 2009; 51(9): 602-618. Go to original source...
    19. Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med. 2004; 351: 1097-1105. Go to original source... Go to PubMed...
    20. Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med. 2004; 55: 373-394. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.